Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
AstraZeneca
Colorcon
Express Scripts
Moodys

Last Updated: June 27, 2022

Horizon Pharma Usa Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for HORIZON PHARMA USA, and when can generic versions of HORIZON PHARMA USA drugs launch?

HORIZON PHARMA USA has one approved drug.

There are twelve US patents protecting HORIZON PHARMA USA drugs.

There are forty-nine patent family members on HORIZON PHARMA USA drugs in thirty-three countries and ten supplementary protection certificates in nine countries.

Summary for Horizon Pharma Usa
International Patents:49
US Patents:12
Tradenames:1
Ingredients:1
NDAs:1
Patent Litigation for Horizon Pharma Usa: See patent lawsuits for Horizon Pharma Usa

Drugs and US Patents for Horizon Pharma Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Pharma Usa PROCYSBI cysteamine bitartrate GRANULE, DELAYED RELEASE;ORAL 213491-001 Feb 14, 2020 RX Yes No 10,143,665 See Plans and Pricing See Plans and Pricing
Horizon Pharma Usa PROCYSBI cysteamine bitartrate GRANULE, DELAYED RELEASE;ORAL 213491-002 Feb 14, 2020 RX Yes Yes 9,173,851*PED See Plans and Pricing Y See Plans and Pricing
Horizon Pharma Usa PROCYSBI cysteamine bitartrate GRANULE, DELAYED RELEASE;ORAL 213491-001 Feb 14, 2020 RX Yes No 9,233,077*PED See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Horizon Pharma Usa Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1919458 CR 2014 00013 Denmark See Plans and Pricing PRODUCT NAME: CYSTEAMIN, HERUNDER MERCAPTAMINBITARTRAT; REG. NO/DATE: EU/1/13/861 20130906
1919458 300649 Netherlands See Plans and Pricing PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910
1919458 C 2014 012 Romania See Plans and Pricing PRODUCT NAME: CISTEAMINABITARTRAT; NATIONAL AUTHORISATION NUMBER: EU/1/13/861; DATE OF NATIONAL AUTHORISATION: 20130906; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/861; DATE OF FIRST AUTHORISATION IN EEA: 20130906
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Express Scripts
Moodys
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.